RAPT Therapeutics Inc RAPT
$58.02 $0.04 (0.07%) 1D
Last Updated: Mar 02, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
RAPT Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, RAPT Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
RAPT Therapeutics Inc. Stock Analysis RAPT
United States Health Care Small Cap Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
RAPT Therapeutics Inc (RAPT) Chart
Financial Metrics & Statements of RAPT Therapeutics Inc (RAPT)
FAQ's for RAPT Therapeutics Inc (RAPT)
- As of August 2026, RAPT Therapeutics Inc RAPT is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes RAPT Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in RAPT Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of RAPT Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of RAPT Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of RAPT Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for RAPT Therapeutics Inc (RAPT)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
